The Semaglutide Patent Puzzle: Evergreening and the Uphill Battle for Indian Generics Post-2026 Semaglutide, Novo Nordisks blockbuster GLP-1 receptor agonist marketed as Ozempic and Wegovy, has revolutionized the management of type 2 diabetes and obesity
It has been used as a supportive treatment in the management of certain liver diseases and in cancer therapy
Lu CW, Yang KC, Chang HH, Lee LT, Chen CY, Huang KC
HIF-1 can be activated by a variety of ROS
Anti-inflammatory cytokine expression: The peptide shifts cytokine profiles toward anti-inflammatory patterns, reducing chronic inflammation that delays healing
For more lab tips, company updates, and insights into the world of peptide research, make sure you're following our page on Facebook